Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism

References

• Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur. J. Vasc. Endovasc. Surg.25(1), 1–5 (2003).
   PubMed Web of Science ®Google Scholar
• McKelvie PA. Autopsy evidence of pulmonary thromboembolism. Med. J. Aust.160(3), 127–128 (1994).
   PubMedGoogle Scholar
• Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(3 Suppl.), S338–S400 (2004).
   PubMedGoogle Scholar
• Segal JB, Streiff MB, Hofmann LV, Thornton K, Bass EB. Management of venous thromboembolism: a systematic review for a practice guideline. Ann. Intern. Med.146(3), 211–222 (2007).
   PubMed Web of Science ®Google Scholar
• Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med.354(14), 1477–1488 (2006).
   PubMed Web of Science ®Google Scholar
• Lee S, Gibson CM. Enoxaparin in acute coronary syndromes. Expert Rev. Cardiovasc. Ther.5(3), 387–399 (2007).
   PubMedGoogle Scholar
• Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J. Thromb. Haemost.1(9), 1906–1913 (2003).
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med.349(2), 146–153 (2003).
   PubMed Web of Science ®Google Scholar
• Baglin T, Barrowcliffe TW, Cohen A et al. Guidelines on the use and monitoring of heparin. Br. J. Haematol.133(1), 19–34 (2006).
   PubMed Web of Science ®Google Scholar
• Planès A. Review of bemiparin sodium – a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Expert Opin. Pharmacother.4(9), 1551–1561 (2003).
   PubMed Web of Science ®Google Scholar
• García Frade LJ, Peñarrubia Ponce MJ. Chemical structure-activity ratio of the low molecular weight heparins (HBPM). Towards a second generation of low molecular weight heparins? Rev. Iberoamer. Tromb. Hemostasia13, 7–13 (2000).
   Google Scholar
• Rocha E, Imberti D, Paschina E. Low-molecular-weight heparins: before or after surgery? New concepts and evidence: Congress report from the Sigma Tau/ROVI Satellite Symposium (Rome, Italy, 13 November 2006). Clin. Drug Investig.27(5), 357–366 (2007).
   PubMedGoogle Scholar
• Chapman TM, Goa KL. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs63(21), 2357–2377 (2003).
   PubMedGoogle Scholar
• Depasse F, González de Suso MJ, Lagoutte I, Fontcuberta J, Borrell M, Samama MM. Comparative study of the pharmacokinetic profiles of two LMWH-bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)-administered subcutaneously to healthy male volunteers. Thromb. Res.109(2–3), 109–117 (2003).
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J. Thromb. Haemost.5(5), 955–962 (2007).
   PubMed Web of Science ®Google Scholar
• Bates SM, Weitz JI. The status of new anticoagulants. Br. J. Haematol.134(1), 3–19 (2006).
   PubMed Web of Science ®Google Scholar
• Christidou FN, Frangia TK, Bamichas GI et al. Comparison of two low-molecular weight heparins (LMWH), tinzaparin and bemiparin, during hemodialysis. Int. J. Clin. Pharmacol. Ther.43(7), 335–338 (2005).
   PubMedGoogle Scholar
• Borrell M, Antonijoan RM, Ortiz R et al. Pharmacokinetic profile of two LMWH: bemiparin 3500 IU and enoxaparin 4000 IU after sc administration in healthy volunteers (18th Congress of the International Society of Thrombosis and Haemostasis. Paris, France, 2001). Thromb. Haemost.86(Suppl.), CD3578 (2001).
   Google Scholar
• Hoppensteadt DA, Jeske W, Fareed J, Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul. Fibrinolysis.6(Suppl. 1), S57–S64 (1995).
   Google Scholar
• Falkon L, Garí M, Sáenz-Campos D, Antonijoan R, Barbanoj M, Fontcuberta J. Kinetic behaviour of the TFPI and anti-FXa effects, after the injection of a LMWH(RO-11) in healthy subjects. Thromb. Haemost.73(4), 728–729 (1995).
   PubMedGoogle Scholar
• Falkon L, Garí M, Barbanoj M, Amiral J, Fontcuberta J. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic sc doses. Blood Coagul. Fibrinolysis9(2), 137–141 (1998).
   PubMed Web of Science ®Google Scholar
• Kakkar VV, Howes J, Sharma V, Kadziola Z; The Bemiparin Assessment group. A comparative, double-blind, randomized trial of a new second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism. Thromb. Haemost.83, 523–529 (2000).
   PubMedGoogle Scholar
• Navarro-Quilis A, Castellet E, Rocha E et al. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J. Thromb. Haemost.1(3), 425–432 (2003).
   PubMedGoogle Scholar
• Honorato J, Gómez-Outes A, Navarro-Quilis A, Martínez-González J, Rocha E, Planès A. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics22(13), 885–894 (2004).
   PubMed Web of Science ®Google Scholar
• Abad JI, Gómez-Outes A, Martínez-González J et al. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery. Arch. Orthop. Trauma Surg.127(8), 665–670 (2007).
   PubMedGoogle Scholar
• Otero-Fernández R, Gómez-Outes A, Martínez-González J et al. Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice. Clin. Appl. Thromb. Hemost.14(1), 75–83 (2008).
   PubMedGoogle Scholar
• Balibrea JL, Altimiras J, Larruzea I et al. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. Int. J. Surg.5(2), 114–119 (2007).
   PubMedGoogle Scholar
• Constans M, Santamaria A, Mateo J, Pujol N, Souto JC, Fontcuberta J. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int. J. Clin. Pract.61(2), 212–217 (2007).
   PubMed Web of Science ®Google Scholar
• Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch. Intern. Med.164(12), 1319–1326 (2004).
   PubMedGoogle Scholar
• Spyropoulos AC, Turpie AG. Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. Curr. Opin. Pulm. Med.11(5), 373–379 (2005).
   PubMed Web of Science ®Google Scholar
• Miras-Parra F, Navascués-Martínez E, Gómez-Outes A et al. Utilisation and safety of bemiparin, a low-molecular-weight heparin, in medical patients: a prospective, uncontrolled cohort study. Clin. Drug Investig.25(7), 463–472 (2005).
   PubMedGoogle Scholar
• Prieto Seva AJ. Safety and effectiveness of bemiparin in the prevention of venous thromboembolic disease in nursing home patients. Rev. Esp. Geriatr. Gerontol.42, 20–26 (2007).
   Google Scholar
• Rodríguez-Mañas L, Gómez-Huelgas R, Monteagudo G, Maeso R, Gómez-Outes A, Martínez-González J. Bemiparin thromboprophylaxis in elderly medical patients: the “ANCIANOS” study. J. Thromb. Haemost.5(Suppl. 2), P-T-671 (2007).
   Google Scholar
• Kakkar VV, Gebska M, Kadziola Z et al. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb. Haemost.89(4), 674–680 (2003).
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Rocha E, Martínez-González J, Kakkar VV. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. Pharmacoeconomics24(1), 81–92 (2006).
   PubMedGoogle Scholar
• Santamaría A, Juárez S, Reche A et al. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study. Int. J. Clin. Pract.60(5), 518–525 (2006).
   PubMedGoogle Scholar
• Lecumberri R, Rosario E, Pacho J, Rocha E; FLEBUS Investigators. Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of venous thromboembolism in patients with transient risk factors in standard clinical practice: the FLEBUS study. J. Thromb. Haemost.4(11), 2504–2508 (2006).
   PubMedGoogle Scholar
• Ong BS, Karr MA, Chan DK, Frankel A, Shen Q. Management of pulmonary embolism in the home. Med. J. Aust.183(5), 239–242 (2005).
   PubMedGoogle Scholar
• Siragusa S, Arcara C, Malato A et al. Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann. Oncol.16(Suppl. 4), iv136–iv139 (2005).
   PubMedGoogle Scholar